Literature DB >> 11456310

Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

A Ascherio1, S M Zhang, M A Hernán, I Kawachi, G A Colditz, F E Speizer, W C Willett.   

Abstract

Results of case-control studies and of a prospective investigation in men suggest that consumption of coffee could protect against the risk of Parkinson's disease, but the active constituent is not clear. To address the hypothesis that caffeine is protective against Parkinson's disease, we examined the relationship of coffee and caffeine consumption to the risk of this disease among participants in two ongoing cohorts, the Health Professionals' Follow-Up Study (HPFS) and the Nurses' Health Study (NHS). The study population comprised 47,351 men and 88,565 women who were free of Parkinson's disease, stroke, or cancer at baseline. A comprehensive life style and dietary questionnaire was completed by the participants at baseline and updated every two to four years. During the follow-up (10 years in men, 16 years in women), we documented a total of 288 incident cases of Parkinson's disease. Among men, after adjustment for age and smoking, the relative risk of Parkinson's disease was 0.42 (95% CI: 0.23-0.78; p for trend < 0.001) for men in the top one-fifth of caffeine intake compared to those in the bottom one-fifth. An inverse association was also observed with consumption of coffee (p for trend = 0.004), caffeine from noncoffee sources (p for trend < 0.001), and tea (p for trend = 0.02) but not decaffeinated coffee. Among women, the relationship between caffeine or coffee intake and risk of Parkinson's disease was U-shaped, with the lowest risk observed at moderate intakes (1-3 cups of coffee/day, or the third quintile of caffeine consumption). These results support a possible protective effect of moderate doses of caffeine on risk of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11456310     DOI: 10.1002/ana.1052

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  182 in total

Review 1.  Genetics of caffeine consumption and responses to caffeine.

Authors:  Amy Yang; Abraham A Palmer; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2010-06-09       Impact factor: 4.530

Review 2.  Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both?

Authors:  Rachel Saunders-Pullman
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

3.  Restless legs syndrome and Parkinson's disease in men.

Authors:  Xiang Gao; Michael A Schwarzschild; Eilis J O'Reilly; Hao Wang; Alberto Ascherio
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 4.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 5.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 6.  Beneficial and detrimental role of adenosine signaling in diseases and therapy.

Authors:  Hong Liu; Yang Xia
Journal:  J Appl Physiol (1985)       Date:  2015-08-27

7.  Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.

Authors:  Iris Y Kim; Éilis J O'Reilly; Katherine C Hughes; Xiang Gao; Michael A Schwarzschild; Marjorie L McCullough; Marian T Hannan; Rebecca A Betensky; Alberto Ascherio
Journal:  Mov Disord       Date:  2018-01-10       Impact factor: 10.338

8.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

9.  Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease.

Authors:  Kelly Claire Simon; Honglei Chen; Michael Schwarzschild; Alberto Ascherio
Journal:  Neurology       Date:  2007-08-29       Impact factor: 9.910

10.  Erectile function and risk of Parkinson's disease.

Authors:  Xiang Gao; Honglei Chen; Michael A Schwarzschild; Dale B Glasser; Giancarlo Logroscino; Eric B Rimm; Alberto Ascherio
Journal:  Am J Epidemiol       Date:  2007-09-17       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.